I get lots of email about my articles that are published here. Sometimes, it’s about grammar or spelling (and the grammar KGB can be uncivil at times). Sometimes, it’s compliments or questions about what I’ve written. Rarely, they’re rude and usually include quite immature comments about the location of my head. However, I recently received an email that is more or less polite, but is filled with so many errors and logical fallacies, that I thought it should be critiqued publicly.
Here are my point-by-point comments about the email:
I stumbled across your blog and could not believe what I was reading about the safety of Gardasil. As a mother of a Gardasil injured daughter, your profuse endorsement made me skeptical. I want to begin by saying I am not anti-vaccine; I am anti-Gardasil. Continue reading “I get an email about Gardasil”
In next week’s issue of Forbes, Matthew Herper, the magazine’s medical editor, penned the article, The Gardasil Problem: How The U.S. Lost Faith In A Promising Vaccine, an insightful analysis of why Gardasil, the vaccine for human papillomavirus (HPV), has not become as important to vaccination strategies as measles or whooping cough. All vaccines keep you alive, even if the disease does not appear to be scary. There’s a belief, especially amongst the anti-vaccination crowd, that measles is just a few spots, and there are few risks to being infected. The risk of severe complications is small, but significant.
On the other hand, the HPV vaccine does one thing and does it well–it prevents an HPV infection. Human papillomavirus, a sexually transmitted disease, causes 70% of cervical cancers, 80% of anal cancers, 60% of vaginal cancers, and 40% of vulvar cancers. It also prevents the majority of HPV caused oral cancers. In other words, these diseases are in a different league of danger. And they can be prevented. Continue reading “Why do Americans hate Gardasil?”
The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of males aged 11 or 12 years with HPV4 administered as a 3-dose series (recommendation category: A, evidence type: 2§). The vaccination series can be started beginning at age 9 years. Vaccination with HPV4 is recommended for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series. Males aged 22 through 26 years may be vaccinated. Continue reading “CDC makes recommendations on the use of HPV vaccine in males”